ViroGates ASOCSE:VIRO 44 Operating Margin % is -220.26% as of Mar. 2026. GuruFocus rates OCSE:VIRO with a GF Score™ of 44/100 and a GF Value™ of kr6.80 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, ViroGates AS ranks worse than 83.7% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. ViroGates AS's Operating Income for the
three
months ended in Mar. 2026 was kr-2.87 Mil. ViroGates AS's Revenue for the
three
months ended in Mar. 2026 was kr1.30 Mil. Therefore, ViroGates AS's Operating Margin % for the quarter that ended in Mar. 2026 was -220.26%.
Good Sign:
ViroGates AS operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for ViroGates AS's Operating Margin % or its related term are showing as below:
OCSE:VIRO'
s Operating Margin % Range Over the Past 10 Years
Min: -550.61 Med: -215.85 Max: -71.36
Current: -117.6
OCSE:VIRO's Operating Margin % is ranked worse than 83.7% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 3.465
vs OCSE:VIRO: -117.60
ViroGates AS's 5-Year Average Operating Margin % Growth Rate was 13.60% per year.
ViroGates AS's Operating Income for the
three
months ended in Mar. 2026 was kr-2.87 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was kr-10.59 Mil.
ViroGates AS (OCSE:VIRO) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
ViroGates AS Operating Margin % Related Terms
ViroGates AS Operating Margin % Historical Data
* Premium members only.
The historical data trend for ViroGates AS's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:VIRO vs ABT, SYK, MDT: Operating Margin % Comparison
For the Medical Devices subindustry, ViroGates AS's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ViroGates AS Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's Operating Margin % distribution charts can be found below:
* The bar in red indicates where ViroGates AS's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
ViroGates AS's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ViroGates AS (OCSE:VIRO) has a Operating Margin % of -220.26% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on ViroGates AS and its competitors. According to the industry distribution chart, ViroGates AS ranks #683 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 83.7%.
Is ViroGates AS's Operating Margin % too high?
ViroGates AS's current Operating Margin % is -220.26%. Based on the distribution chart, ViroGates AS ranks #683 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ViroGates AS has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's Operating Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ViroGates AS ranks #683 out of 816 companies for Operating Margin %. This places ViroGates AS in the lower half of its industry. The industry median Operating Margin % is 3.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.47, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on ViroGates AS and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ViroGates AS's current Operating Margin % is -220.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
Based on GuruFocus' analysis, ViroGates AS (OCSE:VIRO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.80, compared to a current price of kr10.20 — trading 50% above its estimated fair value. The current Operating Margin % is -220.26%. ViroGates AS's overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For ViroGates AS (OCSE:VIRO), the current Operating Margin % is -220.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ViroGates AS (OCSE:VIRO) Overvalued in 2026?
Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued.
The current stock price of kr10.20 is trading 50% above its estimated GF Value™ of kr6.80.
GuruFocus considers ViroGates AS to be Significantly Overvalued.
Key valuation signals for OCSE:VIRO:
Operating Margin %: -220.26%
GF Value™: kr6.80 vs. price of kr10.20 (50% above fair value)
No single metric tells the full story. See the OCSE:VIRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
44GF Score
Get the complete analysis for OCSE:VIRO
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:VIRO has been successfully added to your 
